Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 339

recruiting
3 975
countries
28
conditions
2 109

10 388 trials match your criteria

Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years

Breast cancer

Not yet recruiting

Discontinuation of anti‑HER2 therapy guided by ctDNA in patients with HER2‑positive metastatic breast cancer receiving pertuzumab and trastuzumab

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years

Transplant rejection

Not yet recruiting

Evaluating mezagitamab in adults with late antibody-mediated rejection after kidney transplant

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Mezagitamab

Overweight

Not yet recruiting

Study of Orforglipron in Overweight Adults at Risk of Developing Obesity‑Related Complications or Class 1 Obesity

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years

Petosemtamab versus cetuximab plus drug combination as first‑line treatment for adults with metastatic left‑sided colorectal cancer

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years

Secondary immunodeficiency

Not yet recruiting

Study of Human Normal Immunoglobulin in Adults with Secondary Immune Deficiency after CAR T‑cell or T‑cell Redirecting Therapy for Hematologic Malignancies

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Piclidenoson

Osimertinib and drug combination in metastatic non‑small cell lung cancer with targetable genomic driver alterations

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab

Thrombosis prophylaxis

Not yet recruiting

Randomized trial of standard vs high-dose enoxaparin and sodium chloride for preventing clots in critically ill ICU patients at high risk of thrombosis

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years

VEXAS syndrome

Not yet recruiting

A Randomized, Double‑Blind, Placebo‑Controlled Study of Momelotinib Dihydrochloride Monohydrate in Patients with VEXAS Syndrome

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.